Human CCL25/TECK ELISA Kit (NR-E10105)
search
  • Human CCL25/TECK ELISA Kit (NR-E10105)

Human CCL25/TECK ELISA Kit

Catalog # NR-E10105

Print

$625.00
Quantity

For research use only. Not for diagnostic or therapeutic use, or for human or veterinary use. Sold only to research institutions and qualified laboratory professionals. Not for sale to individuals for personal use.

Assay Range

62.5--4000 pg/mL

Sensitivity

10.0 pg/mL

Size

96T

Storage

Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC

Assay Principle

Sandwich ELISA

Sample volume

100 µL final volume, dilution factor varies on samples

Detection Method

Chromogenic

 

 

Kit Components

 

 1. Recombinant Human CCL25 standard: 2 vials

 2. One 96-well plate precoated with anti- Human CCL25 Ab

 3. Sample diluent buffer: 12 mL - 1

 4. Detection antibody: 130 µL, dilution 1:100

 5. Streptavidin-HRP: 130 µL, dilution 1:100

 6. Antibody diluent buffer: 12 mL x1   

 7. Streptavidin-HRP diluent buffer: 12 mL x1

 8. TMB developing agent: 10 mL x1

9. Stop solution: 10 mL x1.

10. Washing solution (20x): 25 mL x1.

 

 

Background

 

C-C motif chemokine 25 (CCL25), also known as small-inducible cytokine A25 or Thymus-expressed chemokine (TECK), is a small cytokine belonging to the CC chemokine family. CCL25 is expressed in thymus, small intestine, and small bowel. In the thymus, CCL25 is produced by the major CD11b- CD11c+ dendritic cell population. CCL25 is a ligand for the cytokine receptor CCR9. It is reported that CCR9 is expressed on thymocytes, gamma/delta T cells, immature dendritic cells, lamina propria mononuclear cells in the small bowel, gut homing CD4+ and CD8+ memory T cells that co-express the α4β7 integrin molecule, melanoma cells and melanoma cell lines and a variety of tumor cell lines. Except for CCR9, CCL25 also binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4. CCL25 may play a role in T-cell development. Recombinant CCL25 exhibits chemotactic activity on thymocytes, macrophages, THP-1 cells, and dendritics cells but is inactive on peripheral blood lymphocytes and neutrophils. In addition to its role in cell migration, CCL25-induced signaling through CCR9 exhibits an anti-apoptosis regulatory function. For example, CCL25 induces resistance to TNF-α-mediated apoptosis in MOLT-4, T-ALL and T-CLL cells perhaps by induction of the inhibitor of apoptosis Livin. CCL25 may also participate in cycloheximide-mediated apoptosis. Clinically, increase in CCR9+ lymphocytes and CCL25 expression in the inflamed bowel has been associated with the pathogenesis of Crohn’s disease.

New